Group 1 - The core viewpoint of the article is that Jinhe Biological has announced a significant decline in its expected net profit for the fiscal year 2025, projecting a range of 30 million to 42 million yuan compared to 100.20 million yuan in the same period last year [2] Group 2 - The expected net profit for 2025 is estimated to be between 30 million and 42 million yuan [2] - The previous year's net profit was reported at 100.20 million yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

Core Viewpoint - The company is strategically acquiring Jilin Youben to enhance its capabilities in African swine fever vaccine research and production, aiming to increase market share and core competitiveness in the animal vaccine sector [1]. Group 1: Acquisition and Strategic Goals - The acquisition of Jilin Youben is aimed at improving the speed of research and production transformation for African swine fever vaccines [1]. - The company plans to expand its market share in the animal vaccine field through this acquisition [1]. Group 2: Compliance and Safety Upgrades - Jilin Youben and Jinhe Youben have upgraded their facilities to meet the safety requirements for vaccine production and testing, achieving biosafety level three compliance by specific dates in 2025 [1]. - By the end of Q3 2025, the company will have met all necessary qualifications for conducting clinical trials for the African swine fever vaccine [1]. Group 3: Challenges in Vaccine Development - Jilin Youben is facing challenges in finalizing a technology licensing contract with the patent transferor, which is crucial for the production and testing of the African swine fever vaccine [2]. - The company has recognized the high technical difficulty and lengthy regulatory approval process associated with African swine fever vaccine development, leading to uncertainties in project timelines and performance [2]. - As a result of these challenges, the company has decided to suspend the research and application of the freeze-dried inactivated African swine fever vaccine [2].

本报告期，公司兽用化学药品板块销售持续向好，主要产品金霉素内外销市场销量齐增，特别是海外市 场销量继续增长。公司六期工程项目投产后，产量增加，保障了国内外市场供货需求，创造了更多利 润。环保服务板块营业收入继续增加，持续提供较多的业绩贡献。 格隆汇1月30日丨金河生物(002688.SZ)公布，预计2025年归属于上市公司股东的净利润3,000万元～ 4,200万元，比上年同期下降70.06%～58.08%，扣除非经常性损益后的净利润950万元～1,350万元，比 上年同期下降88.66%～83.89%。 ...

Group 1 - The company Jinhe Biological announced that as of the disclosure date, the total external guarantee balance of the company and its subsidiaries is approximately 673 million yuan, which includes the expected new guarantee and excludes the subsidiary's guarantee to the company of 460 million yuan, accounting for 29.95% of the company's audited net assets attributable to the parent company for 2024 [1] - The expected new guarantee amount is approximately 121 million yuan, which accounts for 5.37% of the company's audited net assets attributable to the parent company for 2024 [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reportedly busy with orders scheduled until 2028, operating in three shifts and maintaining 24-hour production lines [1]

Core Viewpoint - The company has decided to suspend the research and application of the African Swine Fever freeze-dried inactivated vaccine due to uncertainties in project progress and high R&D difficulties [1] Group 1: Company Actions - On January 30, 2026, the company's board of directors approved the suspension of the African Swine Fever vaccine project [1] - The company’s subsidiary, Jinhai Youben, acquired 60% equity of Jilin Youben for 288 million yuan to enter the African Swine Fever vaccine research and production [1] Group 2: Project Status - As of the end of the third quarter of 2025, all relevant qualifications for the project had met the requirements [1] - Disagreements with the patent transferor over key terms have led to uncertainties in project progress [1] Group 3: Financial Implications - The suspension of the project will result in goodwill impairment but will not have a significant adverse impact on existing business operations [1]

平安证券股份有限公司 关于金河生物科技股份有限公司 变更部分募集资金用途的核查意见 平安证券股份有限公司（以下简称"保荐机构"）作为金河生物科技股份有 限公司（以下简称"金河生物"或"公司"）的持续督导券商，根据《证券发行 上市保荐业务管理办法》《深圳证券交易所股票上市规则》《上市公司募集资金监 管规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关法 律法规和规范性文件的要求，对金河生物变更部分募集资金用途的事项进行了核 查，具体如下： 一、变更募集资金投资项目的概述 | | | 变更前募投项目 | | | | | | 变更后募投项目 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 项目名 | 实施 | 原计划拟 | 截至2026年1 | 截至 | 2026 | 年 | 项目名称 | 实 | 拟变更投 | | 称 | 主体 | 使用募集 | 月 日已投 25 | 月 日剩 1 25 | | | 施 | | | | 入新项目 | ...

证券代码：002688 证券简称：金河生物 公告编号:2026-011 金河生物科技股份有限公司 关于变更募集资金用途的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"金河生物"、"公司"）于2026 年1月30日召开第六届董事会第三十六次会议，审议通过了《关于变更募集资金 用途的议案》。根据公司实际经营需要及未来发展规划，为进一步提高募集资 金使用效率，合理配置公司资源，公司董事会同意将2021年度非公开发行股票 募投项目"动物疫苗生产基地建设项目（一期）"尚未投入的募集资金用途变 更为"能源系统和发酵系统优化提升项目"和"3,500吨/年粉剂、颗粒剂自动 化密闭生产线项目"。该议案尚需提交股东会审议通过方可实施，具体情况公 告如下： 一、变更募集资金投资项目的概述 （一）募集资金的基本情况 根据2020年12月4日中国证券监督管理委员会（以下简称"中国证监会"） 核发的《关于核准金河生物科技股份有限公司非公开发行股票的批复》（证监 许可[2020]3344号）文核准，公司获准非公开发行145,132,7 ...

金河生物科技股份有限公司 关于计提商誉减值准备的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"、"金河生物"）于 2026 年 1 月 30 日召开第六届董事会第三十六次会议审议通过了《关于计提商誉减值 准备的议案》，该议案尚需提交股东会审议。 为更加真实、准确地反映公司的财务状况、资产价值和经营情况，根据《企 业会计准则》、中国证监会《会计监管风险提示第 8 号—商誉减值》、财政部《企 业会计准则第 8 号—资产减值》、《深圳证券交易所股票上市规则》等相关规定， 基于谨慎性原则，公司对前期收购吉林百思万可生物科技有限公司（现更名为： 金河佑本（吉林）生物科技有限公司，以下简称"吉林佑本"）形成的商誉计提 减值准备，具体内容如下： 一、商誉形成情况说明 证券代码：002688 证券简称：金河生物 公告编号：2026-009 （一）商誉的形成 2023 年 5 月 24 日，公司召开第六届董事会第二次会议审议通过了《关于控 股子公司以股权转让及增资方式取得吉林百思万可生物科技有限公司 60%股权 的议 ...

证券代码：002688 证券简称：金河生物 公告编号：2026-008 金河生物科技股份有限公司 关于中止非洲猪瘟冻干灭活疫苗研发和申报事项的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"、"金河生物"）于 2026 年 1 月 30 日召开第六届董事会第三十六次会议以 9 票同意，0 票反对，0 票弃权 审议通过了《关于中止非洲猪瘟冻干灭活疫苗研发和申报事项的议案》。 1 重点提到"中试单位的生产和检验等条件不符合要求"的问题，吉林佑本和金河 佑本分别对非洲猪瘟疫苗生产车间和非洲猪瘟疫苗检验动物房等设施进行了三 级防护升级和资质验收。2025 年 1 月 25 日，吉林佑本疫苗生产车间通过了生物 安全三级防护检查验收；2025 年 7 月 27 日，金河佑本检验用攻毒动物房及其活 毒废水处理设施以及防护措施通过了生物安全三级防护检查验收。同时为了将来 开展非洲猪瘟疫苗临床试验，金河佑本于 2025 年 8 月 28 日通过了兽药 GCP 猪安 全性试验和猪有效性试验项目增项验收。至 2025 年第 ...